{"id":130446,"date":"2026-09-14T11:45:46","date_gmt":"2026-09-14T11:45:46","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/130446\/"},"modified":"2026-09-14T11:45:46","modified_gmt":"2026-09-14T11:45:46","slug":"novartis-stock-prices-rise-after-positive-multiple-sclerosis-drug-trial-results","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/130446\/","title":{"rendered":"Novartis Stock Prices Rise After Positive Multiple Sclerosis Drug Trial Results"},"content":{"rendered":"<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1qg6i2u e1hwu21o0\"><a data-type=\"company\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/CH\/XSWX\/NOVN\" target=\"_blank\" class=\"ekxajjj0 css-i0lbhy-OverridedLink\" rel=\"nofollow noopener\">Novartis<\/a> <a color=\"var(--color-inkSubtle)\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/CH\/XSWX\/NOVN\" class=\"css-1fr2kw9-ChicletStyle e1vl9ktx2\" rel=\"nofollow noopener\" target=\"_blank\">NOVN -0.09%decrease; down pointing triangle<\/a> shares rose after the drugmaker reported positive results from two late-stage trials in the most common form of multiple sclerosis, saying its new pill helped patients experience fewer flare-ups.<\/p>\n<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1qg6i2u e1hwu21o0\">Shares in Novartis were up 4.5% in European midday trading Tuesday, taking their year-to-date gain to 18%.<\/p>\n<p class=\"css-16aepit e1jdulti0\">Copyright \u00a92026 Dow Jones &amp; Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis NOVN -0.09%decrease; down pointing triangle shares rose after the drugmaker reported positive results from two late-stage trials&hellip;\n","protected":false},"author":2,"featured_media":130447,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[23188,10486,6276,6277,25359,6274,1126,6273,2115,6286,230,6275,834,16097,2783,1002,55694,4128,25348,55699,55695,6288,25353,25352,1831,63380,228,5779,153,37943,37939,37940,42046,63381,63379,1289,25362,25354,25361,25349,6263,206,25358,3708,337,10728,25356,1138,25351,37944,338,25350,25363,12081,6285,6268,6278,6279],"class_list":["post-130446","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-allergy","tag-autoimmune-diseases","tag-ce-exclusion-filter","tag-ce-industry-news-filter","tag-chnovn","tag-content-types","tag-corporate","tag-corporate-industrial-news","tag-development","tag-disruptions","tag-earnings","tag-factiva-filters","tag-financial-performance","tag-gcapi","tag-general-news","tag-health","tag-health-medicine","tag-healthcare","tag-healthcare-life-sciences","tag-immune-health","tag-immune-health-allergy","tag-industrial-news","tag-industrial-property-rights","tag-intellectual-property-rights","tag-life-sciences","tag-linkendrnrealtime-linkedarticle-dnco20260901002248","tag-manufacturing","tag-medicine","tag-multiple-sclerosis","tag-neuroactive","tag-neuroactive-psychotropic-drugs","tag-neurodegenerative-disease-drugs","tag-neurodegenerative-diseases","tag-neurological-health","tag-neurological-health-neurology","tag-neurology","tag-new-product","tag-new-product-service-testing","tag-new-products","tag-new-products-services","tag-newsplus","tag-novartis","tag-novn-eb","tag-patents","tag-pharmaceuticals","tag-political","tag-political-general-news","tag-products","tag-products-services","tag-psychotropic-drugs","tag-research","tag-research-development","tag-service-testing","tag-services","tag-share-price-movement","tag-share-price-movement-disruptions","tag-synd","tag-wsj-pro-wsj-com"],"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/130446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=130446"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/130446\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/130447"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=130446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=130446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=130446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}